^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    BCMA-targeted CAR-T immunotherapy

    Related drugs:
    Apply
    A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant (NCT05393804)
    Phase 2
    Memorial Sloan Kettering Cancer Center
    Recruiting
    Last update posted :
    02/20/2025
    Initiation :
    05/20/2022
    Primary completion :
    05/01/2025
    Completion :
    05/01/2025
    SDC1
    |
    Abecma (idecabtagene vicleucel)
    Ciltacabtagene Autoleucel in High-Risk Smoldering Multiple Myeloma (CAR-HiRiSMM) (NCT06574126)
    Phase 2
    PETHEMA Foundation
    Recruiting
    Last update posted :
    10/26/2024
    Initiation :
    09/30/2024
    Primary completion :
    09/30/2032
    Completion :
    09/30/2032
    CD4
    |
    Carvykti (ciltacabtagene autoleucel)
    Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System (CARTinNS) (NCT04561557)
    Phase 1
    Tongji Hospital
    Recruiting
    Last update posted :
    05/07/2024
    Initiation :
    09/22/2020
    Primary completion :
    02/22/2027
    Completion :
    05/31/2027
    CD8 • IL6 • CD4
    |
    cyclophosphamide • fludarabine IV • Fucaso (equecabtagene autoleucel)
    A Phase I Trial to Establish the Safety and Maximum Tolerated Dose of High-affinity Autologous BCMA-targeting Chimeric Antigen Receptor (CAR) T-cells in Patients With Relapsed and Refractory B-cell Malignancies (CARLOTTA01) (NCT05836896)
    Phase 1
    Technische Universität Dresden
    Recruiting
    Last update posted :
    02/20/2024
    Initiation :
    02/15/2024
    Primary completion :
    06/01/2025
    Completion :
    06/01/2026
    CD31 • SLAMF7
    |
    CD38 positive
    |
    MDC-CAR-BCMA001
    Phase I Trial of BCMA-TGF-BETA CAR-T Cells in Relapsed, Refractory Myeloma (NCT05976555)
    Phase 1
    Medical College of Wisconsin
    Not yet recruiting
    Last update posted :
    01/15/2024
    Initiation :
    06/01/2024
    Primary completion :
    05/01/2027
    Completion :
    05/01/2028
    TGFB1
    MM CAR-T to Upgrade Response BMTCTN1902 (NCT05032820)
    Phase 2
    Marcelo Pasquini, MD
    Active, not recruiting
    Last update posted :
    01/08/2024
    Initiation :
    01/05/2022
    Primary completion :
    01/01/2025
    Completion :
    04/01/2025
    CD34
    |
    lenalidomide • cyclophosphamide • fludarabine IV • Abecma (idecabtagene vicleucel)
    First in Human Study of the Infusion of ARI0003 Cells in Relapsed/Refractory to Treatment B-cell Aggressive Lymphoma (CARTD-BG-1) (NCT06097455)
    Phase 1
    Fundacion Clinic per a la Recerca Biomédica
    Not yet recruiting
    Last update posted :
    10/26/2023
    Initiation :
    01/15/2024
    Primary completion :
    04/15/2025
    Completion :
    01/15/2027
    TNFRSF17
    Immunotherapy With BCMA CAR-T Cells in Treating Patients With BCMA Positive Relapsed or Refractory Multiple Myeloma (NCT03338972)
    Phase 1
    Fred Hutchinson Cancer Center
    Completed
    Last update posted :
    09/08/2023
    Initiation :
    11/29/2017
    Primary completion :
    05/03/2021
    Completion :
    03/22/2022
    SDC1
    |
    SDC1 expression
    |
    cyclophosphamide • fludarabine IV • FCARH143 • FHVH-BCMA-T • cyclophosphamide intravenous
    A Study of MCARH109 and MCARH125 in People With Multiple Myeloma (NCT05431608)
    Phase 1
    Memorial Sloan Kettering Cancer Center
    Recruiting
    Last update posted :
    07/14/2023
    Initiation :
    06/20/2022
    Primary completion :
    06/20/2024
    Completion :
    06/20/2024
    SDC1
    |
    MCARH109 • MCARH125
    CAR- PRISM (PRecision Intervention Smoldering Myeloma) (NCT05767359)
    Phase 2
    Dana-Farber Cancer Institute
    Recruiting
    Last update posted :
    06/19/2023
    Initiation :
    04/19/2023
    Primary completion :
    01/15/2026
    Completion :
    01/15/2040
    TP53
    |
    TP53 mutation • Chr t(4;14) • Chr t(14;16)
    |
    cyclophosphamide • fludarabine IV • Carvykti (ciltacabtagene autoleucel)
    Safety and Efficacy of BCMA-Targeted CAR-T Therapy for Relapsed/Refractory Multiple Myeloma (NCT04272151)
    Phase 1/2
    Chongqing Precision Biotech Co., Ltd
    Recruiting
    Last update posted :
    04/18/2023
    Initiation :
    12/01/2019
    Primary completion :
    12/31/2023
    Completion :
    07/01/2024
    IL6
    |
    BCMA CAR-T cell therapy
    a Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma (NCT04776330)
    Phase 1/2
    Chongqing Precision Biotech Co., Ltd
    Recruiting
    Last update posted :
    04/18/2023
    Initiation :
    03/07/2021
    Primary completion :
    12/31/2023
    Completion :
    07/01/2024
    IL6
    |
    BCMA CAR-T cell therapy
    Novel CAR-T Cell Therapy in the Treatment of Hematopoietic and Lymphoid Malignancies (NCT05513612)
    Phase 1
    Shanghai Pudong Hospital
    Withdrawn
    Last update posted :
    03/01/2023
    Initiation :
    08/01/2020
    Primary completion :
    12/31/2025
    Completion :
    12/31/2026
    CD19
    |
    CD19 expression
    |
    cyclophosphamide • fludarabine IV • Autologous CAR-T cells
    A Study of LCAR-B38M CAR-T Cells, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Chinese Participants With Relapsed or Refractory Multiple Myeloma (CARTIFAN-1) (NCT03758417)
    Phase 2
    Nanjing Legend Biotech Co.
    Recruiting
    Last update posted :
    12/28/2022
    Initiation :
    01/23/2019
    Primary completion :
    02/16/2026
    Completion :
    02/16/2026
    CD8 • IL6 • IL2RA • CD4 • IL10
    |
    Carvykti (ciltacabtagene autoleucel)
    Human BCMA Targeted T Cells Injection（BCMA CAR-T）for Subjects With R/R MM (NCT05594797)
    Phase 2
    Hrain Biotechnology Co., Ltd.
    Recruiting
    Last update posted :
    12/09/2022
    Initiation :
    07/12/2022
    Primary completion :
    07/31/2025
    Completion :
    07/31/2027
    TNFA • IL2 • IL10 • CRP
    |
    anti-BCMA CAR-T cells
    The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies (NCT05618041)
    Phase N/A
    Hebei Senlang Biotechnology Inc., Ltd.
    Recruiting
    Last update posted :
    12/06/2022
    Initiation :
    09/07/2022
    Primary completion :
    09/06/2024
    Completion :
    12/06/2024
    CD8 • IL6 • CD4 • IL10
    |
    cyclophosphamide • senl_BCMA
    Study of FasT CAR-T GC012F Injection in High Risk TE NDMM Patients (GC012F-32) (NCT04935580)
    Phase 1/2
    Shanghai Changzheng Hospital
    Recruiting
    Last update posted :
    08/03/2022
    Initiation :
    06/28/2021
    Primary completion :
    07/01/2023
    Completion :
    07/01/2023
    IFNG • IL6 • IL10
    |
    AZD0120
    A Study of a Fully Human BCMA-targeting CAR (CT103A) Combined With Selinexor in Patients With Relapsed/Refractory Extramedullary Multiple Myeloma (NCT05201118)
    Phase 1
    Chunrui Li
    Recruiting
    Last update posted :
    05/24/2022
    Initiation :
    01/01/2022
    Primary completion :
    12/31/2022
    Completion :
    12/31/2023
    IL6
    |
    Xpovio (selinexor) • Fucaso (equecabtagene autoleucel)
    A Study of CAR-T Cells Targeting Both BCMA and GPRC5D in Treatment of Relapsed or Refractory Multiple Myeloma (NCT05325801)
    Phase 1
    Zhejiang University
    Not yet recruiting
    Last update posted :
    04/13/2022
    Initiation :
    04/01/2022
    Primary completion :
    03/01/2024
    Completion :
    03/01/2025
    GPRC5D
    |
    BM-ca • OriC321
    A Study of Fully Human BCMA CAR-T (CT103A) in Patients With Newly Diagnosed High-risk Multiple Myeloma (FUMANBA-2) (NCT05181501)
    Phase 1
    Nanjing IASO Biotherapeutics Co.,Ltd
    Not yet recruiting
    Last update posted :
    01/06/2022
    Initiation :
    04/01/2022
    Primary completion :
    04/01/2024
    Completion :
    04/01/2039
    IL6
    |
    Fucaso (equecabtagene autoleucel)
    Autologous CAR-T/TCR-T Cell Immunotherapy for Solid Malignancies (NCT03941626)
    Phase 1/2
    Shenzhen BinDeBio Ltd.
    Recruiting
    Last update posted :
    02/04/2021
    Initiation :
    09/01/2019
    Primary completion :
    05/01/2021
    Completion :
    12/01/2021
    HLA-A • MSLN • CTAG1B
    |
    HLA-A*02:01 • MSLN positive • HLA-A positive
    |
    cyclophosphamide • multi-target gene-modified CAR-T/TCR-T cell immunotherapy
    Immunotherapy With BCMA CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma (NCT04447573)
    Phase N/A
    Hebei Senlang Biotechnology Inc., Ltd.
    Recruiting
    Last update posted :
    09/29/2020
    Initiation :
    06/30/2020
    Primary completion :
    08/30/2022
    Completion :
    12/30/2022
    IFNG • IL6 • TNFA • IL10
    |
    cyclophosphamide • SENL-B19 • senl_BCMA
    A Study of BCMA/CD19 Dual-Target CAR-T Cell Immunotherapy for Relapsed or Refractory MM (NCT04412889)
    Phase 1
    Hebei Yanda Ludaopei Hospital
    Not yet recruiting
    Last update posted :
    06/02/2020
    Initiation :
    06/01/2020
    Primary completion :
    12/01/2022
    Completion :
    12/01/2022
    CD19
    |
    CD19 expression
    |
    AZD0120
    Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies (NCT03638206)
    Phase 1/2
    Shenzhen BinDeBio Ltd.
    Recruiting
    Last update posted :
    12/11/2019
    Initiation :
    03/01/2018
    Primary completion :
    03/01/2023
    Completion :
    03/01/2023
    MET • CD19 • HLA-A • MSLN • CD22 • CD33 • CTAG1B
    |
    HLA-A*02:01 • CD19 expression • HLA-A positive
    |
    cyclophosphamide • CAR-T cell immunotherapy • multi-target gene-modified CAR-T/TCR-T cell immunotherapy
    A Study of BCMA/CD19 Dual-Target CAR-T Cell Immunotherapy for Relapsed or Refractory Multiple Myeloma (PGC0008) (NCT04182581)
    Phase 1
    Xijing Hospital
    Unknown status
    Last update posted :
    12/02/2019
    Initiation :
    10/15/2019
    Primary completion :
    09/01/2020
    Completion :
    05/01/2021
    CD19
    |
    CD19 expression
    |
    AZD0120
    Safety and Efficiency Study of BCMA-PD1-CART Cells in Relapsed/Refractory Multiple Myeloma (NCT04162119)
    Phase 2
    Chinese PLA General Hospital
    Recruiting
    Last update posted :
    11/18/2019
    Initiation :
    07/07/2019
    Primary completion :
    10/10/2021
    Completion :
    10/10/2022
    PD-1
    |
    cyclophosphamide • BCMA-PD1-CART Cells
    Study of T Cells Targeting CD138/BCMA/CD19/More Antigens (CART-138/BCMA/19/More) for Chemotherapy Refractory and Relapsed Multiple Myeloma (NCT03196414)
    Phase 1/2
    The First Affiliated Hospital of Soochow Univer...
    Recruiting
    Last update posted :
    05/02/2019
    Initiation :
    09/01/2016
    Primary completion :
    09/01/2026
    Completion :
    12/01/2026
    SDC1
    |
    SDC1 positive
    |
    cyclophosphamide • fludarabine IV • CART-138 • CART-138/BCMA/19/more